Given the fact that the patients with relapsed NBs gradually acquire p53 mutations and become resistant to chemotherapies while p73 is rarely mutated in human cancer, the strategic targeting of the p73-mediated apoptotic pathway might be of therapeutic benefit. This evidence concerns the gene TP53 and cancer.